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Abstract
Purpose: To measure prothrombin fragments (F1+2) and 
thrombin-antithrombin complex (TAT) in vitreous and sub-
retinal fluid (SRF) of rhegmatogenous retinal detachment 
(RRD) patients and to validate and further specify our earlier 
finding of increased thrombin activity in patients with prolif-
erative vitreoretinopathy (PVR). Methods: F1+2 and TAT 
were measured in 31 vitreous and 16 SRF samples using the 
Enzygnost® immunoassays. Results: We found significant 
levels of F1+2 and TAT in the vitreous of all patients with RRD 
compared to patients with macular hole or macular pucker. 
However, there was no significant difference between pa-
tients who would develop PVR in the future, had established 
PVR, and patients with uncomplicated RRD both in vitreous 
concentrations of F1+2 (Kruskal-Wallis p = 0.963) and TAT 
(p = 0.516). Conclusion: The analysis of F1+2 and TAT con-
firmed significant thrombin generation in both vitreous and 
SRF of patients with RRD. An imbalance between the throm-
bin regulation mechanisms TAT and α2-macroglobulin pos-
sibly explains the difference from our previous findings.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Activation of the coagulation cascade has recently 
been identified as a potential factor in the development of 
proliferative vitreoretinopathy (PVR) [1]. We found sig-
nificantly higher intravitreal thrombin concentrations in 
patients with established PVR and demonstrated that in-
travitreal thrombin stimulates retinal pigment epithelial 
cells to produce pro-inflammatory and pro-fibrotic me-
diators [1, 2].
To validate and further specify our earlier finding of 
increased thrombin activity in patients with PVR and to 
gain more insight into the different regulatory mecha-
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nism of thrombin in ocular fluids, we explored two addi-
tional variables. The first is the concentration of the pro-
thrombin activation fragment (F1+2), which is a measure 
of the amount of thrombin generated from prothrombin. 
The second is the concentration of the thrombin-anti-
thrombin complex (TAT) which is a measure of the 
amount of thrombin inhibited by antithrombin. 
We further asked the question whether thrombin gen-
eration – marked by F1+2 and TAT – was different in 
patients with rhegmatogenous retinal detachment (RRD) 
who would develop PVR in the future or had established 
PVR, than in patients with uncomplicated RRD. Lastly, 
we discuss the implications for intervention with dabiga-
tran, a reversible direct thrombin inhibitor. 
Methods
Sample Collection
For the TAT and F1+2 analyses, we used vitreous fluid and sub-
retinal fluid (SRF) samples from the Rotterdam Eye Hospital Bio-
bank. Vitreous fluid or SRF are waste materials which are removed 
during a vitrectomy procedure or scleral buckling procedure, re-
spectively. All patients gave their consent for the use of rest mate-
rial for research.
Undiluted vitreous (1–1.5 mL) had been obtained at the start 
of vitrectomy before opening the infusion line. Undiluted SRF had 
been obtained by drainage through a 23-gauge needle mounted on 
a 2-mL syringe without a plunger [3]. Vitreous and SRF were im-
mediately injected into Eppendorf tubes, provided with a unique 
number, and stored at –80  ° C. The location in the freezer and rel-
evant information about the sample were noted on the registration 
form and later entered into an Access database (Microsoft Of-
fice®).
We searched the biobank database for samples from patients 
who had undergone surgery for one of four conditions: RRD, PVR, 
a macular hole or a macular pucker. For patients with samples 
from RRD surgery, we checked their patient file to see whether 
they had undergone surgery for PVR later on. Samples from pa-
tients with a macular hole or macular pucker were included as 
controls. Samples from the biobank do not contain specific stabi-
lisers. In vitro activation of coagulation seems negligible based on 
tests with vitreous and sodium citrate (unpublished data).
F1+2 Analysis
The quantification of the F1+2 prothrombin fragment was per-
formed using the Enzygnost® F1+2 monoclonal immunoassay 
(Siemens Healthcare Diagnostics Products, Marburg, Germany). 
According to the manufacturer’s instructions, the samples were 
thawed using a water bath (+37  ° C) for 10 min. We diluted the 
sample 5 times – based on previous experience – using the sample 
buffer. Processing of samples and standard solution were per-
formed according to the manufacturer’s instructions [4].
Absorbance was measured at a wavelength of 450 nm using a 
spectrophotometer. The concentrations of F1+2 in the samples 
were derived from the constructed reference curve.
TAT Analysis
For the quantification of TAT, we used the Enzygnost® TAT 
micro immunoassay (Siemens Healthcare Diagnostics Products, 
Marburg, Germany). Based on previous experience the samples 
were diluted 10 times using the sample buffer. Further processing 
of samples and standard solution were performed according to the 
manufacturer’s instructions [5].
Absorbance was measured at a wavelength of 492 nm using a 
spectrophotometer. The concentrations of TAT in the samples 
were derived from the constructed reference curve and were con-
verted from µg/L to pmol/L using the molecular weight (MW) of 
the TAT complex of 96 kDa. 
Statistical Analysis
Data were separately analysed for vitreous fluid and SRF. The 
results in vitreous fluid were analysed using the Kruskal-Wallis 
test. The results in SRF were analysed using the Mann-Whitney U 
test. A sub-analysis was performed for the three RRD groups. The 
relationship between F1+2 and TAT was tested using Spearman’s 
correlation coefficient. A p value < 0.05 was considered significant. 
Analyses were performed with IBM SPSS statistics version 23 (IBM 
Corp., Armonk, NY, USA).
Results
A total of 47 samples were analysed. Distribution of 
samples across groups differed and was subjected to avail-
ability. We were able to obtain 31 vitreous samples and 16 
SRF samples. SRF was only available for primary RRD 
surgeries and thus groups 3 and 4. 
F1+2 Analysis
Concentrations of F1+2 in vitreous differed signifi-
cantly between the 5 groups (p = 0.008). The values in the 
two control groups were consistently low, while the con-
centration in the three RRD groups showed a large varia-
tion (Fig. 1). A Kruskal-Wallis sub-analysis in the three 
RRD groups could not detect a difference (p = 0.963). In 
addition, the F1+2 concentration in the SRF sample from 
the one patient who would, later on, develop PVR was not 
significantly different than the samples from the other 
RRD patients. The upper limit of quantification (ULQ) 
was 6,000 pmol/L and the lower limit of quantification 
(LLQ) was 35 pmol/L (both are shown as dotted lines). 
Values above the ULQ are shown as ULQ, values below 
the LLQ are shown as LLQ/2. 
TAT Analysis
In Figure 2, the results are shown from the TAT mea-
surements for both vitreous and SRF. Concentrations of 
TAT in vitreous differed significantly between the 5 
groups (p = 0.002). The values in the two control groups 
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were again consistently low. A Kruskal-Wallis sub-anal-
ysis in the three RRD groups could not detect a difference 
(p = 0.516). A difference in the TAT concentration in SRF 
between the two groups could not be detected. The ULQ 
was 6,250 pmol/L and the LLQ 208 pmol/L (both are 
shown as dotted lines). Values above the ULQ are shown 
as ULQ, values below the LLQ are shown as LLQ/2. 
Correlation between F1+2 and TAT
The graph in Figure 3 shows the relationship between 
F1+2 and TAT. The production of thrombin marked as 
F1+2 was significantly related to the concentration of 
TAT both in vitreous (rs = 0.84, p < 0.001) and SRF (rs = 
0.93, p < 0.001). The slope suggests that in vitreous 60% 
of thrombin was bound to antithrombin and in SRF 70%. 
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Fig. 1. F1+2 measurements for both vitre-
ous and subretinal fluid. The upper limit of 
quantification (ULQ) was 6,000 pmol/L 
and the lower limit of quantification (LLQ) 
was 35 pmol/L (both are shown as dotted 
lines). Values above the ULQ are shown as 
ULQ, values below the LLQ are shown as 
LLQ/2. MPCK, macular pucker; MHOLE, 
macular hole; RRD, rhegmatogenous reti-
nal detachment; PVR, established prolifer-
ative vitreoretinopathy; RRD, later PVR, 
sample is from primary RRD surgery, pa-
tient developed PVR in later stage.
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Fig. 2. TAT measurements for both vitre-
ous and subretinal fluid. The upper limit of 
quantification (ULQ) was 6,250 pmol/L 
and the lower limit of quantification (LLQ) 
was 208 pmol /L (both are shown as dotted 
lines). Values above the ULQ are shown as 
ULQ, values below the LLQ are shown as 
LLQ/2. MPCK, macular pucker; MHOLE, 
macular hole; RRD, rhegmatogenous reti-
nal detachment; PVR, established prolifer-
ative vitreoretinopathy; RRD, later PVR, 
sample is from primary RRD surgery, pa-
tient developed PVR in later stage.
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Discussion
These results of two indirect measures of thrombin 
formation confirm our previous results that significantly 
more thrombin was generated in vitreous fluids of pa-
tients with RRD in contrast to patients with a macular 
hole or macular pucker (Fig. 1, 2) [1]. In contrast to our 
previous experiment, which showed significantly higher 
thrombin activity in established PVR, we could not detect 
a difference in F1+2 and TAT values between patients 
with uncomplicated RRD and patients with established 
PVR. These findings are important because our more di-
rect measurements of thrombin activity were possibly not 
accurate and straightforward. 
Interestingly, the median concentrations of F1+2 and 
TAT that we found in vitreous and SRF of RRD patients 
were much higher than in normal plasma. The median 
concentration of F1+2 was approximately 10 times high-
er than in plasma (normal range 69–229 pmol/L) and the 
median concentration of TAT was approximately 100 
times higher than in plasma (normal range 20–40 pmol/L) 
[4, 5]. Our values of TAT were similar to those in vitreous 
recently reported by Ehrlich et al. [6]. These high values 
argue in favour of local thrombin activation. 
Also the ratio of F1+2 versus TAT conforms with local 
thrombin activation. In plasma, TAT is cleared about 10 
times faster by the liver from the circulation than F1+2 
(8 min vs. 90 min), which results in a difference in molar 
concentrations and a ratio of approximately 0.1 [7]. In the 
ocular fluids, the molar concentration ratio was closer to 
1 (Fig. 3) indicating the formation of both F1+2 and TAT 
in the absence of differential clearance related to liver 
function in the circulation. The general higher levels in 
vitreous and SRF may be further explained by accumula-
tion from slower clearance of the molecules from this 
compartment. When only the production determines the 
concentration, we expect a strong correlation between 
F1+2 and TAT. The Spearman correlation coefficient was 
indeed rather strong (rs = 0.84 and rs = 0.93) and the slope 
suggests that thrombin is 60–70% bound to antithrombin 
(Fig. 3). The remaining 30–40% is possibly bound to oth-
er inhibitors such as α2-macroglobulin (α2M) or recep-
tors.
What did we measure previously? In the previous ex-
periments, we used the small thrombin-specific chromo-
genic substrate Tos-Gly-Pro-Arg-pNA (MW 662.7 Da) 
for the measurements of intravitreal thrombin activity 
[1]. Although the substrate is very well split by thrombin, 
other serine proteases such as plasma kallikrein and plas-
min are also known to act on the substrate due to its small 
MW. Small synthetic substrates do not provide sufficient 
resemblance to the large natural substrates of thrombin, 
which was initially articulated by Gaffney et al. [8]. To 
distinguish between thrombin activity and activity of oth-
er enzymes, we duplicated the measurements with the ad-
dition of a very specific and irreversible inhibitor of 
thrombin: hirudin (MW 7 kDa) [1]. Specific thrombin 
activity in vitreous fluid was identified and quantified 
based on the difference in activity between vitreous fluid 
with and without hirudin. We assumed that what we re-
corded was only free thrombin activity. 
At the time of those experiments, we were not aware 
of the possibility that thrombin bound to one of its in-
hibitors named α2M could still interact with small sub-
strates and hirudin. In vivo, thrombin is mainly regulated 
by two inhibitors. The primary thrombin inhibitor is an-
tithrombin, which forms the inactive TAT complex. The 
action of antithrombin can be increased significantly by 
the endogenous proteoglycan heparin [9]. The second in-
hibitor is α2M. α2M is a large plasma protein (725 kDa) 
that upon binding undergoes a conformational change 
such that the α2M folds around thrombin and partially 
shields its active site [10]. This prevents the cleavage of 
large substrates such as fibrinogen (340 kDa) nearly com-
pletely but is not much effective for small substrates. The 
complex of α2M with enzymes is rapidly cleared from the 
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Fig. 3. Correlations of F1+2 and TAT values in subretinal fluid 
(triangles) and vitreous (circles). The dashed line represents the 
trend line of subretinal fluid and the dotted line the trend line of 
vitreous. Lower limit of quantification values are included as being 
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circulation; however, in a relatively enclosed compart-
ment such as the eye or in vitro, a very slow remaining 
interaction of the complex with larger substrates (MW up 
to at least 20 kDa) remains possible and may continue to 
show thrombin activity [10, 11]. Such slow interaction 
was shown for α2M-bound thrombin with hirudin on a 
time scale up to 4 h and for α2M-bound trypsin with soy-
bean trypsin inhibitor (MW 20 kDa) on a time scale up to 
40 h [11–13]. In the assay we used, we recorded the activ-
ity at different time points up to 10 h and based our anal-
ysis on the 8-hour values. Re-inspecting the time course 
of activity showed a progressive inhibition by hirudin 
similar to what was reported by Pochon and Steinbuch 
[11]. We now conclude that the previous report mainly 
concerned α2M-bound thrombin. The fact that thrombin 
is bound to α2M does not change the hypothesis that 
thrombin plays a role in the development of PVR as the 
presence of the complex shows that thrombin had been 
formed. In addition, our previous experiment did show a 
significant increase in the production of CCL2, CXCL8, 
IL-6, and IL-12 in ARPE-19 cells after incubation with 
vitreous [1]. These effects were abolished by hirudin, 
which makes it unlikely that other enzymes than throm-
bin in the vitreous played a role. 
The total amount of thrombin that has been locally ac-
tive is probably better described by the concentration of 
F1+2 than the sum of TAT and our previous measure-
ment of (α2M-bound) thrombin. Although we now know 
that it is highly likely that all previously measured throm-
bin activity was bound to α2M, the exact quantification 
from that information is uncertain because of a question 
about the stoichiometry of the inhibition. We tested the 
hirudin sensitivity of the complex, but α2M possesses two 
binding sites and binds one or two thrombin molecules. 
It is unknown whether hirudin is able to interact with 
both α2M-bound thrombin molecules. For trypsin, it was 
shown that only one of the two α2M-bound trypsin mol-
ecules interacted with soybean trypsin inhibitor [13]. On 
retrospect, we also observed residual activity seen after 
prolonged hirudin inhibition, which might not just be 
from other serine proteases but partly from α2M-bound 
thrombin not inhibited by hirudin. Using the hirudin-
inhibited activity as a measure of thrombin activity – even 
after allowing enough incubation time – might therefore 
underestimate the thrombin activity. 
We found significantly higher (what is now known to 
be) α2M-bound thrombin in patients with established 
PVR than in patients with uncomplicated RRD and pa-
tients who would later develop PVR. Surprisingly, we did 
not find this difference in F1+2 (formation marker) and 
TAT (thrombin portion bound by antithrombin) but 
found a remarkably broad range of values among the 
RRD patients. It will be of interest to know whether or not 
this range in degree of thrombin formation relates further 
to, for example, the size of the detachment or overall 
health of the patient. However, the limited sample size of 
this study rendered it not feasible to explore this.
Another possible explanation for this difference might 
be that not only the amount of thrombin generated causes 
PVR, but an imbalance in the different regulation mecha-
nisms of thrombin determines whether or not thrombin 
causes the development of PVR. We can only speculate 
that the TAT portion is modulated by local heparins and 
that the α2M-bound thrombin portion is responsible for 
the cellular effects. After binding of α2M to a proteinase, 
the resulting conformational change exposes a receptor 
recognition site on the α2M molecule. When this site is 
recognized by an α2M receptor, mainly found on hepato-
cytes, macrophages, and fibroblasts, the complex is inter-
nalized and degraded [10, 14]. Therefore, it is suggested 
that α2M may function as a scavenger for different pep-
tide mediators in inﬂamed tissue and may constitute an 
important mechanism for the regulation and contain-
ment of inﬂammation [14]. In contrast, it was also dem-
onstrated that α2M binds and modulates the biological 
activity of several cytokines [15]. Activated α2M en-
hanced growth responses to TGF-β1 in smooth muscle 
cells and also IL-6 was shown to retain biological activity 
after binding to α2M [16, 17]. It may therefore also func-
tion as a carrier. An imbalance towards more α2M would 
possibly show a less steep slope in the correlation graph 
of F1+2 and TAT; however, there were too few samples 
in the PVR groups to compare slopes.
In view of our hypothesis that the α2M-bound throm-
bin is the active compound in cellular reactions and that 
an imbalance between regulation mechanism plays a role, 
the question arises whether or not an artificial inhibitor 
of thrombin such as dabigatran changes the distribution 
of thrombin between antithrombin and α2M. In an in vi-
tro experiment in plasma, we observed that the presence 
of dabigatran actively changed the distribution among in-
hibitors. With the same concentration of thrombin, we 
found an increasing concentration of TAT with increas-
ing concentrations of dabigatran (unpublished data). 
This is considered to be a consequence of the difference 
in affinity of antithrombin and α2M for thrombin. The 
addition of dabigatran, a reversible inhibitor that com-
petes with antithrombin and α2M for thrombin, results 
in favouring the formation of complexes with the inhibi-
tor with the highest affinity (antithrombin), which would 
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be advantageous if the goal is to have less α2M-bound 
thrombin.
What are the implications of these results for our pro-
posed therapy with the small direct thrombin inhibitor 
dabigatran? The median F1+2 concentration of 2,000 
pmol/L among the RRD groups suggests a four times 
larger thrombin activity than we previously reported [1]. 
A recalculation, however, of the dabigatran concentra-
tion needed to inhibit this amount of thrombin revealed 
no large increase. For an 80% inhibition, a concentration 
of 9.4 ng/mL would be needed [18].
At what point in time and how long thrombin has been 
active remains unclear. However, even when this amount 
of thrombin would be active all at once, the above-calcu-
lated concentration of dabigatran would be able to inhib-
it both free and α2M-bound thrombin [19]. An addition-
al aim of dabigatran treatment in the prevention of PVR 
could be reducing α2M-thrombin formation by shifting 
the balance towards inactive TAT.
In conclusion, the analysis of F1+2 and TAT con-
firmed significant thrombin generation in both vitreous 
and SRF of patients with RRD. Vitreous dabigatran con-
centrations after oral intake would suffice to inhibit this 
amount of thrombin activity. Although we found a sig-
nificant difference between uncomplicated RRD and 
PVR in thrombin activity in our previous study, we could 
not detect a difference in the formation of thrombin and 
inactivation via TAT. Possibly, additional factors such as 
overall health and imbalance between the regulatory 
mechanisms of thrombin play a role in steering an RRD 
towards PVR. A larger study including ASA scores, med-
ication use, peroperative information, and analysis of 
F1+2, TAT, (α2M-bound) thrombin activity, and their 
ratios might give more insight into these factors.
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